insulin icodec investigational ultralongacting basal insulin analogue developed novo nordisk plasma halflife eight compared hours previous longestacting insulin analogue insulin degludec making onceweekly basal like insulin icodec composed two peptide chains linked disulfide bridge however fatty diacidcontaining side chain added strong reversible albumin binding three amino acid substitutions provide molecular stability attenuate insulin receptor binding clearance together modifications prolong insulin icodec international nonproprietary based clinical trial glycemic control found noninferior onceweekly insulin icodec compared oncedaily insulin glargine httpsenwikipediaorgwikiinsulinicodec